ADHD

Desoxyn®
(methamphetamine hydrochloride tablets, USP)
Rx only
METHAMPHETAMINE HAS A HIGH POTENTIAL FOR ABUSE. IT SHOULD THUS BE
TRIED ONLY IN WEIGHT REDUCTION PROGRAMS FOR PATIENTS IN WHOM
ALTERNATIVE THERAPY HAS BEEN INEFFECTIVE. ADMINISTRATION OF
METHAMPHETAMINE FOR PROLONGED PERIODS OF TIME IN OBESITY MAY
LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR
ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING
METHAMPHETAMINE FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO
OTHERS, AND THE DRUG SHOULD BE PRESCRIBED OR DISPENSED
SPARINGLY. MISUSE OF METHAMPHETAMINE MAY CAUSE SUDDEN DEATH AND
SERIOUS CARDIOVASCULAR ADVERSE EVENTS.
DESCRIPTION
DESOXYN® (methamphetamine hydrochloride tablets, USP), chemically known as
(S)-N,α-dimethylbenzeneethanamine hydrochloride, is a member of the amphetamine
group of sympathomimetic amines. It has the following structural formula:
DESOXYN tablets contain 5 mg of methamphetamine hydrochloride for oral
administration.
Inactive Ingredients:
Corn starch, lactose, sodium paraminobenzoate, stearic acid and talc.
CLINICAL PHARMACOLOGY
Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral
actions include elevation of systolic and diastolic blood pressures and weak
bronchodilator and respiratory stimulant action. Drugs of this class used in obesity are
commonly known as “anorectics” or “anorexigenics”. It has not been established,
however, that the action of such drugs in treating obesity is primarily one of appetite
suppression. Other central nervous system actions, or metabolic effects, may be
involved, for example.
Reference ID: 3734642

Adult obese subjects instructed in dietary management and treated with “anorectic”
drugs, lose more weight on the average than those treated with placebo and diet, as
determined in relatively short-term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo-treated
patients is only a fraction of a pound a week. The rate of weight loss is greatest in the
first weeks of therapy for both drug and placebo subjects and tends to decrease in
succeeding weeks. The origins of the increased weight loss due to the various possible
drug effects are not established. The amount of weight loss associated with the use of
an “anorectic” drug varies from trial to trial, and the increased weight loss appears to be
related in part to variables other than the drug prescribed, such as the physicianinvestigator, the population treated, and the diet prescribed. Studies do not permit
conclusions as to the relative importance of the drug and non-drug factors on weight
loss.
The natural history of obesity is measured in years, whereas the studies cited are
restricted to a few weeks duration; thus, the total impact of drug-induced weight loss
over that of diet alone must be considered clinically limited.
The mechanism of action involved in producing the beneficial behavioral changes seen
in hyperkinetic children receiving methamphetamine is unknown.
In humans, methamphetamine is rapidly absorbed from the gastrointestinal tract. The
primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and
deamination. At least seven metabolites have been identified in the urine. The biological
half-life has been reported in the range of 4 to 5 hours. Excretion occurs primarily in the
urine and is dependent on urine pH. Alkaline urine will significantly increase the drug
half-life. Approximately 62% of an oral dose is eliminated in the urine within the first 24
hours with about one-third as intact drug and the remainder as metabolites.
INDICATIONS AND USAGE
Attention Deficit Disorder with Hyperactivity: DESOXYN tablets are indicated as an
integral part of a total treatment program which typically includes other remedial
measures (psychological, educational, social) for a stabilizing effect in children over 6
years of age with a behavioral syndrome characterized by the following group of
developmentally inappropriate symptoms: moderate to severe distractibility, short
attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this
syndrome should not be made with finality when these symptoms are only of
comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability,
and abnormal EEG may or may not be present, and a diagnosis of central nervous
system dysfunction may or may not be warranted.
Exogenous Obesity: as a short-term (i.e., a few weeks) adjunct in a regimen of weight
reduction based on caloric restriction, for patients in whom obesity is refractory to
alternative therapy, e.g., repeated diets, group programs, and other drugs.
Reference ID: 3734642

The limited usefulness of DESOXYN tablets (see CLINICAL PHARMACOLOGY)
should be weighed against possible risks inherent in use of the drug, such as those
described below.
CONTRAINDICATIONS
DESOXYN tablets are contraindicated during or within 14 days following the
administration of monoamine oxidase inhibitors; hypertensive crisis may result. It is also
contraindicated in patients with glaucoma, advanced arteriosclerosis, symptomatic
cardiovascular disease, moderate to severe hypertension, hyperthyroidism or known
hypersensitivity or idiosyncrasy to sympathomimetic amines. Methamphetamine should
not be given to patients who are in an agitated state or who have a history of drug
abuse.
WARNINGS
Tolerance to the anorectic effect usually develops within a few weeks. When this
occurs, the recommended dose should not be exceeded in an attempt to increase the
effect; rather, the drug should be discontinued (see DRUG ABUSE AND
DEPENDENCE).
Serious Cardiovascular Events
Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious
Heart Problems:
 Children and Adolescents: Sudden death has been reported in association with
CNS stimulant treatment at usual doses in children and adolescents with structural
cardiac abnormalities or other serious heart problems. Although some serious heart
problems alone carry an increased risk of sudden death, stimulant products
generally should not be used in children or adolescents with known serious structural
cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other
serious cardiac problems that may place them at increased vulnerability to the
sympathomimetic effects of a stimulant drug.
 Adults: Sudden deaths, stroke, and myocardial infarction have been reported in
adults taking stimulant drugs at usual doses for ADHD. Although the role of
stimulants in these adult cases is also unknown, adults have a greater likelihood
than children of having serious structural cardiac abnormalities, cardiomyopathy,
serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac
problems. Adults with such abnormalities should also generally not be treated with
stimulant drugs.

Hypertension and other Cardiovascular Conditions: Stimulant medications cause a
modest increase in average blood pressure (about 2-4 mmHg) and average heart rate
(about 3-6 bpm), and individuals may have larger increases. While the mean changes
alone would not be expected to have short-term consequences, all patients should be
monitored for larger changes in heart rate and blood pressure. Caution is indicated in
treating patients whose underlying medical conditions might be compromised by
increases in blood pressure or heart rate, e.g., those with pre-existing hypertension,
heart failure, recent myocardial infarction, or ventricular arrhythmia.
Assessing Cardiovascular Status in Patients being Treated with Stimulant
Medications: Children, adolescents, or adults who are being considered for treatment
with stimulant medications should have a careful history (including assessment for a
family history of sudden death or ventricular arrhythmia) and physical exam to assess
for the presence of cardiac disease, and should receive further cardiac evaluation if
findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients
who develop symptoms such as exertional chest pain, unexplained syncope, or other
symptoms suggestive of cardiac disease during stimulant treatment should undergo a
prompt cardiac evaluation.
Psychiatric Adverse Events
Pre-existing Psychosis: Administration of stimulants may exacerbate symptoms of
behavior disturbance and thought disorder in patients with a pre-existing psychotic
disorder.
Bipolar Illness: Particular care should be taken in using stimulants to treat ADHD in
patients with comorbid bipolar disorder because of concern for possible induction of a
mixed/manic episode in such patients. Prior to initiating treatment with a stimulant,
patients with comorbid depressive symptoms should be adequately screened to
determine if they are at risk for bipolar disorder; such screening should include a
detailed psychiatric history, including a family history of suicide, bipolar disorder, and
depression.
Emergence of New Psychotic or Manic Symptoms: Treatment emergent psychotic
or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and
adolescents without a prior history of psychotic illness or mania can be caused by
stimulants at usual doses. If such symptoms occur, consideration should be given to a
possible causal role of the stimulant, and discontinuation of treatment may be
appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such
symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to
methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated
patients compared to 0 in placebo-treated patients.
Reference ID: 3734642

Aggression: Aggressive behavior or hostility is often observed in children and
adolescents with ADHD, and has been reported in clinical trials and the postmarketing
experience of some medications indicated for the treatment of ADHD. Although there is
no systematic evidence that stimulants cause aggressive behavior or hostility, patients
beginning treatment for ADHD should be monitored for the appearance of or worsening
of aggressive behavior or hostility.
Long-Term Suppression of Growth: Careful follow-up of weight and height in children
ages 7 to 10 years who were randomized to either methylphenidate or non-medication
treatment groups over 14 months, as well as in naturalistic subgroups of newly
methylphenidate-treated and non-medication treated children over 36 months (to the
ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment
for 7 days per week throughout the year) have a temporary slowing in growth rate (on
average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight
over 3 years), without evidence of growth rebound during this period of development.
Published data are inadequate to determine whether chronic use of amphetamines may
cause a similar suppression of growth, however, it is anticipated that they likely have
this effect as well. Therefore, growth should be monitored during treatment with
stimulants, and patients who are not growing or gaining height or weight as expected
may need to have their treatment interrupted.
Seizures: There is some clinical evidence that stimulants may lower the convulsive
threshold in patients with prior history of seizures, in patients with prior EEG
abnormalities in absence of seizures, and, very rarely, in patients without a history of
seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug
should be discontinued.
Peripheral Vasculopathy, including Raynaud’s phenomenon: Stimulants, including
DESOXYN, used to treat ADHD are associated with peripheral vasculopathy, including
Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild;
however, very rare sequelae include digital ulceration and/or soft tissue breakdown.
Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in
post-marketing reports at different times and at therapeutic doses in all age groups
throughout the course of treatment. Signs and symptoms generally improve after
reduction in dose or discontinuation of drug. Careful observation for digital changes is
necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g.,
rheumatology referral) may be appropriate for certain patients.
Visual Disturbance: Difficulties with accommodation and blurring of vision have been
reported with stimulant treatment.
PRECAUTIONS
General: DESOXYN tablets should be used with caution in patients with even mild
hypertension.
Reference ID: 3734642

Methamphetamine should not be used to combat fatigue or to replace rest in normal
persons.
Prescribing and dispensing of methamphetamine should be limited to the smallest
amount that is feasible at one time in order to minimize the possibility of overdosage.
Information for Patients: The patient should be informed that methamphetamine may
impair the ability to engage in potentially hazardous activities, such as, operating
machinery or driving a motor vehicle.
Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud’s
phenomenon]
 Instruct patients beginning treatment with DESOXYN about the risk of peripheral
vasculopathy, including Raynaud’s Phenomenon, and associated signs and
symptoms: fingers or toes may feel numb, cool, painful, and/or may change color
from pale, to blue, to red.
 Instruct patients to report to their physician any new numbness, pain, skin color
change, or sensitivity to temperature in fingers or toes.
 Instruct patients to call their physician immediately with any signs of
unexplained wounds appearing on fingers or toes while taking DESOXYN.
 Further clinical evaluation (e.g., rheumatology referral) may be appropriate for
certain patients.
The patient should be cautioned not to increase dosage, except on advice of the
physician.
Prescribers or other health professionals should inform patients, their families, and their
caregivers about the benefits and risks associated with treatment with
methamphetamine and should counsel them in its appropriate use. A patient Medication
Guide is available for DESOXYN. The prescriber or health professional should instruct
patients, their families, and their caregivers to read the Medication Guide and should
assist them in understanding its contents. Patients should be given the opportunity to
discuss the contents of the Medication Guide and to obtain answers to any questions
they may have. The complete text of the Medication Guide is available at
www.recordatirarediseases.com.
Drug Interactions: Insulin requirements in diabetes mellitus may be altered in
association with the use of methamphetamine and the concomitant dietary regimen.
Methamphetamine may decrease the hypotensive effect of guanethidine.
DESOXYN should not be used concurrently with monoamine oxidase inhibitors (see
CONTRAINDICATIONS).
Reference ID: 3734642

Concurrent administration of tricyclic antidepressants and indirect-acting
sympathomimetic amines such as the amphetamines, should be closely supervised and
dosage carefully adjusted.
Phenothiazines are reported in the literature to antagonize the CNS stimulant action of
the amphetamines.
Drug/Laboratory Test Interactions: Literature reports suggest that amphetamines
may be associated with significant elevation of plasma corticosteroids. This should be
considered if determination of plasma corticosteroid levels is desired in a person
receiving amphetamines.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Data are not available on
long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.
Pregnancy
Teratogenic effects: Pregnancy Category C. Methamphetamine has been shown to
have teratogenic and embryocidal effects in mammals given high multiples of the
human dose. There are no adequate and well-controlled studies in pregnant women.
DESOXYN tablets should not be used during pregnancy unless the potential benefit
justifies the potential risk to the fetus.
Nonteratogenic effects: Infants born to mothers dependent on amphetamines have an
increased risk of premature delivery and low birth weight. Also, these infants may
experience symptoms of withdrawal as demonstrated by dysphoria, including agitation
and significant lassitude.
Usage in Nursing Mothers: Amphetamines are excreted in human milk. Mothers
taking amphetamines should be advised to refrain from nursing.
Pediatric Use: Safety and effectiveness for use as an anorectic agent in children below
the age of 12 years have not been established.
Long-term effects of methamphetamine in children have not been established (see
WARNINGS).
Drug treatment is not indicated in all cases of the behavioral syndrome characterized by
moderate to severe distractibility, short attention span, hyperactivity, emotional lability
and impulsivity. It should be considered only in light of the complete history and
evaluation of the child. The decision to prescribe DESOXYN tablets should depend on
the physician’s assessment of the chronicity and severity of the child’s symptoms and
their appropriateness for his/her age. Prescription should not depend solely on the
presence of one or more of the behavioral characteristics.
Reference ID: 3734642

When these symptoms are associated with acute stress reactions, treatment with
DESOXYN tablets is usually not indicated.
Clinical experience suggests that in psychotic children, administration of DESOXYN
tablets may exacerbate symptoms of behavior disturbance and thought disorder.
Amphetamines have been reported to exacerbate motor and phonic tics and Tourette’ s
syndrome. Therefore, clinical evaluation for tics and Tourette’s syndrome in children
and their families should precede use of stimulant medications.
Geriatric Use: Clinical Studies of DESOXYN did not include sufficient numbers of
subjects age 65 years and over to determine whether elderly subjects respond
differently from younger subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger patients. In general, dose
selection for an elderly patient should be cautious, usually starting at the low end of the
dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac
function, and of concomitant disease or other drug therapy observed in this population.
ADVERSE REACTIONS
The following are adverse reactions in decreasing order of severity within each category
that have been reported:
Cardiovascular: Elevation of blood pressure, tachycardia and palpitation. Fatal
cardiorespiratory arrest has been reported, mostly in the context of abuse/misuse.
Central Nervous System: Psychotic episodes have been rarely reported at
recommended doses. Dizziness, dysphoria, overstimulation, euphoria, insomnia,
tremor, restlessness and headache. Exacerbation of motor and phonic tics and
Tourette’s syndrome.
Gastrointestinal: Diarrhea, constipation, dryness of mouth, unpleasant taste and other
gastrointestinal disturbances.
Hypersensitivity: Urticaria.
Endocrine: Impotence and changes in libido; frequent or prolonged erections.
Musculoskeletal: Rhabdomyolysis.
Miscellaneous: Suppression of growth has been reported with the long-term use of
stimulants in children (see WARNINGS).
To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases
Inc. at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reference ID: 3734642

DRUG ABUSE AND DEPENDENCE
Controlled Substance: DESOXYN tablets are subject to control under DEA schedule II.
Abuse: Methamphetamine has been extensively abused. Tolerance, extreme
psychological dependence, and severe social disability have occurred. There are
reports of patients who have increased the dosage to many times that recommended.
Abrupt cessation following prolonged high dosage administration results in extreme
fatigue and mental depression; changes are also noted on the sleep EEG.
Manifestations of chronic intoxication with methamphetamine include severe
dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The
most severe manifestation of chronic intoxication is psychosis often clinically
indistinguishable from schizophrenia. Abuse and/or misuse of methamphetamine have
resulted in death. Fatal cardiorespiratory arrest has been reported in the context of
abuse and/or misuse of methamphetamine.
OVERDOSAGE
Manifestations of acute overdosage with methamphetamine include restlessness,
tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic
states, hyperpyrexia, and rhabdomyolysis. Fatigue and depression usually follow the
central stimulation. Cardiovascular effects include arrhythmias, hypertension or
hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea,
vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in
convulsions and coma.
Consult with a Certified Poison Control Center regarding treatment for up to date
guidance and advice. Management of acute methamphetamine intoxication is largely
symptomatic and includes gastric evacuation, administration of activated charcoal, and
sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit
recommendations in this regard.
Acidification of urine increases methamphetamine excretion, but is believed to increase
risk of acute renal failure if myoglobinuria is present. Intravenous phentolamine
(Regitine*) has been suggested for possible acute, severe hypertension, if this
complicates methamphetamine overdosage. Usually a gradual drop in blood pressure
will result when sufficient sedation has been achieved. Chlorpromazine has been
reported to be useful in decreasing CNS stimulation and sympathomimetic effects.
*Regitine is a registered trademark of Novartis.
DOSAGE AND ADMINISTRATION
DESOXYN tablets are given orally.
Methamphetamine should be administered at the lowest effective dosage, and dosage
should be individually adjusted. Late evening medication should be avoided because of
the resulting insomnia.
Reference ID: 3734642

Attention Deficit Disorder with Hyperactivity: For treatment of children 6 years or
older with a behavioral syndrome characterized by moderate to severe distractibility,
short attention span, hyperactivity, emotional lability and impulsivity: an initial dose of 5
mg DESOXYN once or twice a day is recommended. Daily dosage may be raised in
increments of 5 mg at weekly intervals until an optimum clinical response is achieved.
The usual effective dose is 20 to 25 mg daily. The total daily dose may be given in two
divided doses daily.
Where possible, drug administration should be interrupted occasionally to determine if
there is a recurrence of behavioral symptoms sufficient to require continued therapy.
For Obesity: One 5 mg tablet should be taken one-half hour before each meal.
Treatment should not exceed a few weeks in duration. Methamphetamine is not
recommended for use as an anorectic agent in children under 12 years of age.
HOW SUPPLIED
DESOXYN (methamphetamine hydrochloride tablets, USP) is supplied as white tablets
imprinted with the letters OV on one side and the number 12 on the opposite side,
containing 5 mg methamphetamine hydrochloride in bottles of 100
(NDC 55292-102-01).
Recommended Storage: Store below 86°F (30°C).
Dispense in a USP tight, light resistant container.
Manufactured by:
AbbVie LTD
Barceloneta, PR 00617
For: Recordati Rare Diseases Inc., Lebanon, NJ 08833, U.S.A.
® Trademark of Recordati Rare Diseases Inc.

Revised: February 2015 03-A894-R11

Reference ID: 3734642

MEDICATION GUIDE
Desoxyn®
(Pronounced Dĕ-sŏks-ĭn)

(methamphetamine hydrochloride tablets, USP)

Read the Medication Guide that comes with DESOXYN® before you or your child starts
taking it and each time you get a refill.
There may be new information. This Medication Guide does not take the place of
talking to your or your child’s doctor about your or your child’s treatment with
DESOXYN.
What is the most important information I should know about DESOXYN?
The following have been reported with use of methamphetamine
hydrochloride and other stimulant medicines.

1. Heart-related problems:
   • sudden death in patients who have heart problems or
   heart defects
   • stroke and heart attack in adults
   • increased blood pressure and heart rate
   Tell your or your child’s doctor if you or your child have any heart problems, heart
   defects, high blood pressure, or a family history of these problems.
   Your or your child’s doctor should check you or your child carefully for heart problems
   before starting DESOXYN.
   Your or your child’s doctor should check you or your child’s blood pressure and heart
   rate regularly during treatment with DESOXYN.
   Call your or your child’s doctor right away if you or your child has any signs of
   heart problems such as chest pain, shortness of breath, or fainting while taking
   DESOXYN.
2. Mental (Psychiatric) problems:
   All Patients
   • new or worse behavior and thought problems
   • new or worse bipolar illness
   • new or worse aggressive behavior or hostility
   Children and Teenagers
   • new psychotic symptoms (such as hearing voices, believing

things that are not true, are suspicious) or new manic

symptoms

Tell your or your child’s doctor about any mental problems you or your child have, or
about a family history of suicide, bipolar illness, or depression.
Call your or your child’s doctor right away if you or your child have any new or
worsening mental symptoms or problems while taking DESOXYN, especially
seeing or hearing things that are not real, believing things that are not real, or are
suspicious.
Reference ID: 3734642

3. Circulation problems in fingers and toes [Peripheral vasculopathy, including
   Raynaud’s phenomenon]:
   • fingers or toes may feel numb, cool, painful
   • fingers or toes may change color from pale, to blue, to red
   Tell your doctor if you have or your child has numbness, pain, skin color change, or
   sensitivity to temperature in your fingers or toes.
   Call you your doctor right away if you have or your child has any signs of
   unexplained wounds appearing on fingers or toes while taking DESOXYN.
   What is DESOXYN?
   DESOXYN is a central nervous system stimulant prescription medicine. It is used for
   the treatment of Attention-Deficit Hyperactivity Disorder; (ADHD). DESOXYN may
   help increase attention and decrease impulsiveness and hyperactivity in patients with
   ADHD.
   DESOXYN should be used as a part of a total treatment program for ADHD that may
   include counseling or other therapies.
   DESOXYN is also used short-term, along with a low calorie diet, for weight loss in
   obese patients who have not been able to lose weight on other therapies.
   DESOXYN is a federally controlled substance (CII) because it can be abused or
   lead to dependence. Keep DESOXYN in a safe place to prevent misuse and
   abuse. Selling or giving away DESOXYN may harm others, and
   is against the law.
   Tell your or your child’s doctor if you or your child have (or have a family history of) ever
   abused or been dependent on alcohol, prescription medicines or street drugs.
   Who should not take DESOXYN?
   DESOXYN should not be taken if you or your child:
   • have heart disease or hardening of the arteries
   • have moderate to severe high blood pressure
   • have hyperthyroidism
   • have an eye problem called glaucoma
   • are agitated
   • have a history of drug abuse
   • are taking or have taken within the past 14 days an
   antidepression medicine called a monoamine oxidase

inhibitor or MAOI.

• are sensitive to, allergic to, or had a reaction to other
stimulant medicines
DESOXYN is not recommended for use in children less than 6 years old in the
treatment of ADHD.
DESOXYN may not be right for you or your child. Before starting DESOXYN tell
your or your child’s doctor about all health conditions (or a family history of)
including:
• heart problems, heart defects, high blood pressure
• mental problems including psychosis, mania, bipolar

illness or depression

• tics or Tourette’s syndrome
• thyroid problems
Reference ID: 3734642

• diabetes
• seizures or have had an abnormal brain wave test (EEG)
• circulation problems in fingers and toes
Tell your or your child’s doctor if you or your child is pregnant, planning to become
pregnant, or breastfeeding.
Can DESOXYN be taken with other medicines?

Tell your or your child’s doctor about all of the medicines that you or your child
take including prescription and nonprescription medicines, vitamins, and herbal

supplements.

DESOXYN and some medicines may interact with each other and cause serious side
effects. Sometimes the doses of other medicines will need to be adjusted while taking
DESOXYN.
Your or your child’s doctor will decide whether DESOXYN can be taken with other
medicines.
Especially tell your or your child’s doctor if you or your child takes:
• anti-depression medicines including MAOIs
• anti-psychotic medicines
• blood pressure medicines
• insulin
• seizure medicines
Know the medicines that you or your child takes. Keep a list of your medicines with you
to show your doctor and pharmacist.
Do not start any new medicine while taking DESOXYN without talking to your or
your child’s doctor first.
How should DESOXYN be taken?
• Take DESOXYN exactly as prescribed. Your or your child’s doctor may
adjust the dose until it is right for you or your child.
• DESOXYN is usually taken 1 or 2 times each day.
• From time to time, your or your child’s doctor may stop DESOXYN treatment for
a while to check ADHD symptoms.
• Your or your child’s doctor may do regular checks of the blood, heart, and blood
pressure while taking DESOXYN. Children should have their height and weight
checked often while taking DESOXYN. DESOXYN treatment may be stopped
if a problem is found during these check-ups.
• If you or your child takes too much DESOXYN or overdoses, call your or
your child’s doctor or poison control center right away, or get emergency
treatment.
What are possible side effects of DESOXYN?

See “What is the most important information I should know about DESOXYN?” for
information on reported heart and mental problems.

Other serious side effects include:
• slowing of growth (height and weight) in children
• seizures, mainly in patients with a history of seizures
• eyesight changes or blurred vision
Reference ID: 3734642

Common side effects include:
• fast heart beat • decreased appetite
• tremors • headache
• trouble sleeping • dizziness
• stomach upset • weight loss
• dry mouth
DESOXYN may affect your or your child’s ability to drive or do other dangerous

activities.

Talk to your or your child’s doctor if you or your child has side effects that are
bothersome or do not go away.

This is not a complete list of possible side effects. Ask your or your child’s doctor or
pharmacist for more information.

Call your or your child’s doctor for medical advice about side effects. You may report
side effects to FDA at 1-800-FDA-1088.

How should I store DESOXYN?
• Store DESOXYN in a safe place below 86°F (30°C). Protect from light.
• Keep DESOXYN and all medicines out of the reach of children.
General information about DESOXYN
Medicines are sometimes prescribed for purposes other than those listed in a
Medication Guide. Do not use DESOXYN for a condition for which it was not
prescribed. Do not give DESOXYN to other people, even if they have the same
condition. It may harm them and it is against the law.
This Medication Guide summarizes the most important information about DESOXYN. If
you would like more information, talk with your or your child’s doctor. You can ask your
or your child’s doctor or pharmacist for information about DESOXYN that was written for
healthcare professionals.
For more information about DESOXYN, contact Recordati Rare Diseases Inc. at
1-888-575-8344 or visit www.recordatirarediseases.com.
What are the ingredients in DESOXYN?
Active Ingredient: methamphetamine hydrochloride
Inactive Ingredients: corn starch, lactose, sodium paraminobenzoate, stearic acid and
talc
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Recordati Rare Diseases Inc.

Lebanon, NJ 08833, U.S.A.

® Trademark of Recordati Rare Diseases Inc.

Revised: February 2015 03-A894-R11

Reference ID: 3734642